| [1] |
Michelakos T, Pergolini I, Castillo CF, et al. Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX[J]. Ann Surg, 2019, 269(4):733-740.
|
| [2] |
苗毅．局部进展期胰腺癌综合治疗难点及对策[J]．中国实用外科杂志，2017, 37(7):721-723.
|
| [3] |
孙备，王鑫龙．可能切除胰腺癌概念变迁及其意义[J]．中国实用外科杂志，2017, 38(7):734-737.
|
| [4] |
Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017[J]. Pancreatology, 2018, 18(1):2-11.
|
| [5] |
Katz MHG, Varadhachary GR. Borderline resectable pancreatic cancer-at the crossroads of precision medicine[J]. Cancer, 2019, 125(10):1584-1587.
|
| [6] |
Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial[J]. Ann Surg, 2018, 268(2):215-222.
|
| [7] |
Yoo C, Shin SH, Kim KP, et al. Clinical outcomes of conversion surgery after neoadjuvant chemotherapy in patients with borderline resectable and locally advanced unresectable pancreatic cancer: a single-center, retrospective analysis[J]. Cancers, 2019, 11(3):278-289.
|
| [8] |
曲风智，王刚，孙备，等．临界可切除胰腺癌新辅助治疗的研究进展[J]．中华肝胆外科杂志，2015, 21(3):206-209.
|
| [9] |
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteriain solid tumours:revised RECIST guideline (version1.1)[J]. Eur J Cancer, 2008, 45(2):228-247.
|
| [10] |
Vauthey JN, Dixon E. AHPBA/SSO/SSAT consensus conference on resectable and borderline resectable pancreatic cancer: rationale and overview of the conference[J]. Ann Surg Oncol, 2009, 16(7):1725-1726.
URL
|
| [11] |
Katz MH, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators[J]. Cancer, 2012, 118(23):5749-5756.
|
| [12] |
Baliyan V, Kordbacheh H, Parakh A, et al. Response assessment in pancreatic ductal adenocarcinoma: role of imaging[J]. Abdom Radiol, 2018, 43(2):435-444.
|
| [13] |
Heger U, Sun H, Hinz U, et al.Induction chemotherapy in pancreatic cancer: CA19-9 may predict resectability and survival[J]. HPB, 2019, DOI: 10.1016/j.hpb.2019.06.012[Epub ahead of print]. |
| [14] |
Cassinotto C, Sa-Cunha A, Trillaud H. Radiological evaluation of response to neoadjuvant treatment in pancreatic cancer[J]. Diagn Interv Imaging, 2016, 97(12):1225-1232.
|
| [15] |
Luo G, Liu C, Guo M, et al. Potential biomarkers in Lewis negative patients with pancreatic cancer[J]. Ann Surg, 2017, 265(4):800-805.
|
| [16] |
Bernard V, Kim DU, San Lucas FA, et al. Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer[J]. Gastroenterology, 2019, 156(1):108-118.
|
| [17] |
虞先濬，程合，鹿语，等．进展期胰腺癌新辅助治疗后手术时机选择[J]．中国实用外科杂志，2017, 37(7):748-751.
|
| [18] |
Joo I, Lee JM, Lee ES, et al. Preoperative CT classification of the resectability of pancreatic cancer: interobserver agreement[J]. Radiology, 2019, 293(2):343-349.
|
| [19] |
Miyasaka Y, Ohtsuka T, Kimura R, et al. Neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel for borderline resectable pancreatic cancer potentially improves survival and facilitates surgery[J]. Ann Surg Oncol, 2019, 26(5):1528-1534.
|
| [20] |
Napolitano F, Formisano L, Giardino A, et al. Neoadjuvant treatment in locally advanced pancreatic cancer (LAPC) patients with FOLFIRINOX or gemcitabine nab-paclitaxel: a single-center experience and a literature review[J]. Cancers, 2019, 11(7):981-1000.
|
| [21] |
中国抗癌协会胰腺癌专业委员会．胰腺癌综合诊治指南（2018版）[J]．临床肝胆病杂志，2018, 34(10):2109-2120.
|